Nascent Health’s SoPure stevia gets “no questions” GRAS response from FDA

The GRAS notification covers all steviol glycosides extracted from the stevia leaf, broadening SoPure’s authorized usage status to include its entire stevia portfolio.

Ingredient supplier Nascent Health Sciences LLC (Iselin, NJ) has received a “no questions” letter from FDA in response to a Generally Recognized as Safe (GRAS) notification submitted for the company’s SoPure stevia ingredients. The news about the GRAS notification (GRN 983) was reported by GRAS Associates, a subsidiary of Nutrasource Pharmaceutical and Nutraceutical Services (Guelph, ON, Canada). GRAS Associates compiled and submitted the GRAS Notice to FDA on behalf of Nascent Health Sciences.

The GRAS notification covers all steviol glycosides extracted from the stevia leaf, broadening SoPure’s authorized usage status to include its entire stevia portfolio. “This confirmation expands upon the FDA’s previous No Objection for our Reb A to now include all steviol glycosides we extract from the leaf,” said Hank Wang, technical director, Nascent Health Sciences, in a press release.

He continued: “This now provides our manufacturing customers with confidence knowing that their stevia supply is not only grown naturally and sourced sustainably but is also safe and backed by the most stringent regulatory approvals.” SoPure is already included in a wide range of beverages, baked goods and desserts, condiments and sauces, confections, dairy products, tabletop sweeteners, and personal care products like lipsticks, mouthwashes, toothpaste, and more.

GRAS Associates helps dietary supplement and food ingredient companies with full regulatory scientific services, including establishing ingredient safety, claims substantiation, and technical label review.